Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda raised a $311 million Series E at a $2 billion valuation to advance AI-discovered, nature-derived drugs into trials.
48
Organization
Catalio Capital Management
- Mentions · 7d0
- Mentions · 30d0
- All mentions1
- First seenSep 23, 2026
- Last mentionedSep 23, 2026
Timeline
1 articles · newest firstAppears with
- Envedaorganization · 1
- Recursion Pharmaceuticalsorganization · 1
- Iconiqorganization · 1
Entities are extracted by the model from each article. First seen , last mentioned . Watching keeps it in this browser only (no account); the watchlist page and dashboard alerts use it.